1. Scrip
  2. >>Business
  3. >>Stock Watch

Stock Watch: Cytokinetics – From Certain Villain To Possible Hero

But Positive Phase III Study May Not Result In Big Pharma Acquisition

 
• By Andy Smith

Investors’ euphoria on Cytokinetics’ positive Phase III study may be tempered by its high debt, pass-through royalties, entrenched competition and the FTC in the terms of any transaction.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

When Cytokinetics, Inc. announced the positive results of its Phase III SEQUOIA-HCM study of the cardiac myosin inhibitor aficamten in 282 patients with the rare disease obstructive hypertrophic cardiomyopathy (oHCM) in late December, its investors were quick to forgive Santa’s tardiness and pushed its stock price up by over 82%. By comparison, the NASDAQ Biotech Index (NBI) closed up by under 2% that day. Until the last few days of the year, 2023 had been a year to forget at Cytokinetics with its CEO describing it as “challenging year” after only the first quarter.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Stock Watch

More from Business

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.

In Brief: Sanofi Gains €10bn From Opella Sale

 
• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.